Research programme: PPAR delta agonists - Esperion/Nippon Chemiphar
Latest Information Update: 17 Oct 2007
At a glance
- Originator Nippon Chemiphar
- Class Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
- 15 Jan 2004 Preclinical trials in Cardiovascular disorders in USA (unspecified route)